Public Invitation to Bid: Joint Procurement of Pharmaceuticals for Reiwa 9 (2027)

This tender announcement originates from Japan, sourced through the NHO (National Hospital Organization) Headquarters Procurement. It concerns a joint procurement ('共同入札') for pharmaceuticals for the fiscal year Reiwa 9 (equivalent to approximately 2027). This is a significant procurement initiative aimed at consolidating demand to achieve economies of scale for essential medicines. The tender seeks bids from pharmaceutical manufacturers or authorized distributors capable of supplying a range of specified medications. Key requirements for bidders typically include demonstrating compliance with Japanese pharmaceutical regulations, Good Manufacturing Practices (GMP), and stringent quality control standards. The scope involves the supply of specific drug formulations, dosages, and quantities as detailed in the tender documents, over the designated contract period. Bidders must possess a robust supply chain, ensure timely and secure delivery to NHO facilities, and offer competitive pricing structures. The NHO will evaluate submissions based on the quality and reliability of the pharmaceuticals, the supplier's regulatory compliance, delivery capabilities, and the overall cost-effectiveness of their bid. This tender represents a critical opportunity for pharmaceutical companies to partner with a major healthcare provider in Japan.